iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Glenmark Pharma introduces Nitric Oxide Nasal Spray in partnership with SaNOtize; Stock jumps 2%

9 Feb 2022 , 10:54 AM

Glenmark Pharmaceuticals

In its press release on Wednesday, Glenmark Pharmaceuticals Ltd., a global, innovation-driven pharmaceutical company, announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India, in association with Canadian pharmaceutical company SaNOtize Research & Development Corp. The drug will be available for the treatment of patients with COVID-19 who have a high risk of progression of the disease.

Earlier, Glenmark received approval for marketing and manufacturing from the Drugs Controller General of India (DCGI) for NONS as part of its accelerated approval process.

FabiSpray is Nitric Oxide Nasal Spray explicitly designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties have a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa prevents the virus from incubating and spreading to the lungs, acting as a physical and chemical barrier against the virus.

“As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are glad to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray) and launch it in partnership with SaNOtize. This reaffirms our commitment & dedication to providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option,” commented Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd.

The company conducted Phase 3 clinical trial in adult COVID-19 patients across 20 clinical sites in India. The double-blind, parallel-arm, multicenter study, conducted in 306 patients evaluated the efficacy and safety of Nitric Oxide Nasal Spray versus normal saline nasal spray in non-hospitalized adult patients. All patients received standard supportive care in the study. In its conclusion, there was a reduction in log viral load in the NONS group that was statistically significant and superior to the control (placebo) group (p < 0.05).

Glenmark Pharma is currently trading at Rs492.50 up by Rs7.45 or 1.54% from its previous closing of Rs485.05. The scrip opened at Rs486.15 and has touched a high and low of Rs496.15 and Rs486.15 respectively.

Related Tags

  • Glenmark NDA Approval
  • Glenmark Pharma Drug
  • Glenmark Stock News
  • Glenmark Updates
  • Pharma news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
13 Apr 2024   |   02:33 PM
Images
13 Apr 2024   |   02:30 PM
Images
12 Apr 2024   |   01:37 PM
Images
12 Apr 2024   |   10:20 AM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp